GSK Bexxar No Longer Rituxan Dependent For Non-Hodgkin's Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will promote Bexxar as a "true second-line therapy" in patients who have relapsed after any regimen containing Rituxan and/or chemotherapy. Previously, patients had to be refractory to rituximab prior to considering Bexxar as a therapeutic option.
You may also be interested in...
Corixa Sells Bexxar Rights To GSK As Part Of Restructuring
The cost-cutting effort includes the elimination of 160 positions at the company's South San Francisco and Seattle operations, Corixa says. Copromotion partner GlaxoSmithKline will take over Bexxar development and marketing responsibilities effective Dec. 31.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.